Bevastim
Bevastim is the first biologic medicine (not a chemotherapy) approved by the U.S. Food and Drug Administration (FDA) designed to inhibit angiogenesis. Angiogenesis is the growth of new blood vessels. This process helps a tumor grow and spread by connecting the tumor to the body’s blood supply.
Features
| Product Name | Bevastim |
| Generic Name | Bevacizumab |
| Therapeutic Class | Monoclonal Antibody |
| Formulation | Solution (Liquid) |
| Available Pack Size | 1x1's |
| Available Strength | 100 mg, 400 mg |